Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1)
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1)
Authors
Keywords
Chemo-resistant, Phenoxodiol, Cantrixil, Ovarian cancer, Flavonoids, Super-benzopyran
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 79, Issue 2, Pages 303-314
Publisher
Springer Nature
Online
2016-12-25
DOI
10.1007/s00280-016-3224-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Emerging importance of dietary phytochemicals in fight against cancer: Role in targeting cancer stem cells
- (2016) Amit Kumar Singh et al. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
- TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
- (2016) Ayesha B. Alvero et al. MOLECULAR CANCER THERAPEUTICS
- Phytochemicals in the Fight Against Cancer
- (2016) Kristoffer T. Davidson et al. PATHOLOGY & ONCOLOGY RESEARCH
- Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges
- (2016) Eswar Shankar et al. SEMINARS IN CANCER BIOLOGY
- A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms
- (2015) Monica Cojoc et al. SEMINARS IN CANCER BIOLOGY
- Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors
- (2014) Johanna C. Bendell et al. CANCER
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients
- (2013) J. L. Walker ANNALS OF ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence
- (2013) Ilana Chefetz et al. CELL CYCLE
- A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
- (2013) Shubham Pant et al. INVESTIGATIONAL NEW DRUGS
- Trends in Hospital Volume and Patterns of Referral for Women With Gynecologic Cancers
- (2013) Jason D. Wright et al. OBSTETRICS AND GYNECOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions
- (2012) Isabelle Soerjomataram et al. LANCET
- Constitutive proteasomal degradation of TWIST-1 in epithelial–ovarian cancer stem cells impacts differentiation and metastatic potential
- (2012) G Yin et al. ONCOGENE
- Triphendiol (NV-196), development of a novel therapy for pancreatic cancer
- (2011) Xiaohong Wang et al. ANTI-CANCER DRUGS
- Recent progress in the diagnosis and treatment of ovarian cancer
- (2011) Danijela Jelovac et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance
- (2011) Ayesha B. Alvero et al. CELL CYCLE
- Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells
- (2011) A. B. Alvero et al. MOLECULAR CANCER THERAPEUTICS
- Idronoxil
- (2009) D.M. Brown et al. DRUGS OF THE FUTURE
- Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs
- (2009) Dan-Arin Silasi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Stem-Like Ovarian Cancer Cells Can Serve as Tumor Vascular Progenitors
- (2009) Ayesha B. Alvero et al. STEM CELLS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started